ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform ...
The company recently secured exclusive rights to KLOXXADO nasal spray in the U.S. and Canada, enhancing its portfolio of opioid overdose treatments. On the financial front, Emergent's annual revenue ...
The company recently secured exclusive rights to KLOXXADO nasal spray in the U.S. and Canada, enhancing its portfolio of opioid overdose treatments. On the financial front, Emergent's annual ...
Hikma Partners with Emergent for the Sale of KLOXXADO in the U.S. & Canada 14.01. Hikma Pharma Inks Exclusive Commercial Deal With Emergent BioSolutions For KLOXXADO Nasal Spray 8 Mg ...
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ...
Under the terms of the agreement, Hikma will continue to manufacture KLOXXADO® Nasal Spray 8 mg, which will be integrated into Emergent’s proprietary NARCANDirect™ distribution network.
The pharmaceutical company recently secured exclusive rights to KLOXXADO nasal spray in the U.S. and Canada, complementing its existing portfolio of opioid overdose treatments. This move is part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback